The agency said that although the Akeega with prednisone improved outcomes in all patients with HRR mutations, the benefits were driven by those with BRCA2 mutations.

A large international analysis found no adverse effect of menopausal hormonal therapy among women with high genetic cancer risks.

NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.

The financing comes as the FDA has lifted a clinical hold on the firm's MyPEAK-1 trial testing TN-201 in MYBPC3-associated hypertrophic cardiomyopathy.

Black patients were less likely to receive PARP inhibitors, despite having BRCA1/2 testing and positivity rates comparable to White patients, and were at higher risk of death.

The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...

Challenging federal funding cuts, minimal residual disease, and a busy field of CAR T-cell candidates characterized this year ...

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

Researchers also discussed access barriers at the meeting, and a survey found distance was a major hindrance to CAR-T ...

Researchers at ASH shared Phase III data comparing the pre- and five-year posttreatment adjusted annualized bleeding rates, ...

The AI-driven platform identifies cell cycle deregulation and tumor immune microenvironment dynamics from biopsy images.

Data presented at ASH suggest that the CRISPR therapy could provide a one-time functional cure in children as young as 5 ...